The Department of Veterans Affairs (VA) is preparing to issue Request for Proposal (RFP) 36E79725R0030 for the procurement of Perphenazine Tablets. This is an unrestricted solicitation that will supply not only the VA but also the Department of Defense, the Bureau of Prisons, the Indian Health Service, and Federal Health Care Centers. The successful contractor will ensure a continuous supply for one year, with optional extensions for up to four additional years. The proposal is expected to be released electronically around April 10, 2025, with submissions due by April 24, 2025. Offerors must provide unique NDC numbers and specify the drug name as it appears on the label. The total estimated annual requirements consist of four variations of Perphenazine Tablets, with yearly needs quantified for each dosage. No paper copies of the solicitation will be distributed, and interested parties must keep informed of any updates on SAM.gov. All responsible sources are encouraged to submit a proposal, with primary inquiries directed to the point of contact, Anthony Di Crescenzo, via email.

The document details a government Request for Proposal (RFP) concerning the procurement of Perphenazine tablets for the Department of Veterans Affairs (VA) and Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs. The solicitation outlines the requirements for service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses to compete for a contract to supply specified quantities of the drug across multiple years, including a base year and four option years. Offerors must provide pricing that includes a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product. The contract is aimed at ensuring a consistent supply of pharmaceutical products, adhering to the Drug Supply Chain Security Act (DSCSA), and establishing a structured evaluation process based on Fair Acquisition Regulations (FAR). Moreover, the contractor must maintain compliance with FDA regulations, including Good Manufacturing Practices (cGMP). The contract's overall objective is to streamline the procurement and distribution process, allowing the VA and DoD to efficiently fulfill their pharmaceutical needs while maintaining regulatory compliance and cost-effectiveness.

This government document is an amendment to solicitation 36E79725R0030 from the Department of Veterans Affairs, specifically issued by the OPAL/National Acquisition Center. The primary purpose of the amendment is to extend the due date for submission of offers from April 24, 2025, to May 1, 2025, at 2:30 PM CDT. All other terms and conditions of the solicitation remain unchanged. Offerors are reminded to acknowledge receipt of this amendment, which can be done through various methods including returning copies of the amendment, acknowledgment in submitted offers, or via a separate communication. The amendment underscores the importance of timely submission and adherence to solicitation requirements. The contracting officer responsible for this amendment is Nicholas McGregor, ensuring that all procedural steps are performed in accordance with federal guidelines.